Brief: Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
BRIEF-Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Nov 15 (Reuters) - Summit Therapeutics Inc. SMMT.O:
SUMMIT THERAPEUTICS PROVIDES UPDATE REGARDING IVONESCIMAB BIOLOGICS LICENSE APPLICATION
SUMMIT THERAPEUTICS - FDA CANNOT APPROVE IVONESCIMAB BLA DUE TO LACK OF STATISTICALLY SIGNIFICANT OS IMPROVEMENT
SUMMIT THERAPEUTICS - HARMONI PHASE III STUDY SHOWS STATISTICALLY SIGNIFICANT PFS IMPROVEMENT
SUMMIT THERAPEUTICS - IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES ACCEPTABLE SAFETY PROFILE
SUMMIT THERAPEUTICS - DEVELOPING IVONESCIMAB IN NSCLC, CRC, UC, RCC WITH PHASE II/III TRIALS
SUMMIT THERAPEUTICS - COLLABORATES WITH ASTRAZENECA AND DAIICHI SANKYO ON IVONESCIMAB COMBINATIONS
Source text: ID:nBw8mvwbWa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)